PMCTPharmaCountry
    Accueil

Actualités réglementaires

Évolutions réglementaires FDA, EMA, TGA et mondiales

#Lilly ×

UPDATED
Actualités réglementaires
5 sept. 2026•1 min de lecture
FDA Approves NDA007392 for Secobarbital Sodium Injection (Seconal)
FDA has approved NDA007392 for Seconal Sodium injectable, a secobarbital sodium product by Lilly, with a detailed submission history and discontinued marketing status.
2
UPDATED
Actualités réglementaires
30 août 2026•1 min de lecture
FDA Approves Lilly Methyltestosterone Tablet ANDA080256 (Discontinued)
FDA approved Lilly's ANDA080256 for methyltestosterone tablets (10 mg and 25 mg) buccal/sublingual on Dec 22 1971; both products are now discontinued.